Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
21 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
19 août 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass℠ Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers
19 août 2024 05h05 HE
|
Multiple Myeloma Research Foundation
This MMRF-led collaborative initiative is the largest single sequencing study of multiple myeloma patients to dateCoMMpass findings provide an unprecedented, clearer definition of patients at highest...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
16 août 2024 07h00 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
Groundbreaking Crnic Institute Study Discovers Differences in Oxygen Physiology in People with Down Syndrome
15 août 2024 13h38 HE
|
Global Down Syndrome Foundation
Denver, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to support a groundbreaking new study published in Cell Reports by researchers from its partner and...
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15 août 2024 08h00 HE
|
DiagnaMed Holdings Corp.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
14 août 2024 08h30 HE
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Crnic Institute Clinical Trial Shows JAK Inhibitor Improves Multiple Autoimmune Conditions in Patients with Down Syndrome
13 août 2024 13h48 HE
|
Global Down Syndrome Foundation
Denver, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to support a new study published in eLIFE by researchers from its partner and Affiliate, the Linda...
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
13 août 2024 07h00 HE
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.